JP5745275B2 - 迅速クリアランスポリペプチドの生体内動態 - Google Patents

迅速クリアランスポリペプチドの生体内動態 Download PDF

Info

Publication number
JP5745275B2
JP5745275B2 JP2010538713A JP2010538713A JP5745275B2 JP 5745275 B2 JP5745275 B2 JP 5745275B2 JP 2010538713 A JP2010538713 A JP 2010538713A JP 2010538713 A JP2010538713 A JP 2010538713A JP 5745275 B2 JP5745275 B2 JP 5745275B2
Authority
JP
Japan
Prior art keywords
polypeptide
amino acid
affibodies
isoelectric point
clearance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010538713A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011509926A5 (cg-RX-API-DMAC7.html
JP2011509926A (ja
Inventor
レンデル、クリストファー
ギュネリウッソン、エリン
リンドボルグ、マリン
リー、ブライアン・デューラン
キャッスル、ジェイソン・ウィリアム
シュド、ファイサル・アーメド
マリノ、マイケル・アーネスト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Electric Co
Original Assignee
General Electric Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Electric Co filed Critical General Electric Co
Publication of JP2011509926A publication Critical patent/JP2011509926A/ja
Publication of JP2011509926A5 publication Critical patent/JP2011509926A5/ja
Application granted granted Critical
Publication of JP5745275B2 publication Critical patent/JP5745275B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
JP2010538713A 2007-12-19 2008-12-17 迅速クリアランスポリペプチドの生体内動態 Active JP5745275B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/002,972 2007-12-19
US12/002,972 US8937047B2 (en) 2007-12-19 2007-12-19 Biokinetics of fast-clearing polypeptides
PCT/EP2008/067774 WO2009077569A1 (en) 2007-12-19 2008-12-17 Biokinetics of fast-clearing polypeptides

Publications (3)

Publication Number Publication Date
JP2011509926A JP2011509926A (ja) 2011-03-31
JP2011509926A5 JP2011509926A5 (cg-RX-API-DMAC7.html) 2013-01-31
JP5745275B2 true JP5745275B2 (ja) 2015-07-08

Family

ID=40591871

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010538713A Active JP5745275B2 (ja) 2007-12-19 2008-12-17 迅速クリアランスポリペプチドの生体内動態

Country Status (7)

Country Link
US (1) US8937047B2 (cg-RX-API-DMAC7.html)
EP (1) EP2231706B3 (cg-RX-API-DMAC7.html)
JP (1) JP5745275B2 (cg-RX-API-DMAC7.html)
CN (1) CN101952314B (cg-RX-API-DMAC7.html)
AT (1) ATE529445T1 (cg-RX-API-DMAC7.html)
ES (1) ES2375018T7 (cg-RX-API-DMAC7.html)
WO (1) WO2009077569A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9187535B2 (en) * 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
US8937047B2 (en) * 2007-12-19 2015-01-20 General Electric Company Biokinetics of fast-clearing polypeptides
US8124725B2 (en) * 2007-12-19 2012-02-28 General Electric Company PDGF-Rβ binders
EP2077272A1 (en) * 2007-12-21 2009-07-08 Affibody AB Polypeptide libraries with a predetermined scaffold
EP2072525A1 (en) 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
US20120165650A1 (en) 2010-12-22 2012-06-28 General Electric Company Her2 binders
US10861978B2 (en) 2012-04-02 2020-12-08 Samsung Display Co., Ltd. Display device
CN112870390B (zh) * 2021-01-29 2022-04-22 四川大学华西医院 一种镓68标记的亲合体蛋白pet显像剂及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322678A (en) 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
US6673559B1 (en) 1989-12-27 2004-01-06 The Government Of The United States Of America As Represented By The Department Of Health And Human Services Met proto-oncogene and a method for predicting breast cancer progression
US6271364B1 (en) 1999-02-23 2001-08-07 Amgen Inc. Analogs of NT-3
US6020163A (en) 1997-08-06 2000-02-01 Zymogenetics, Inc. Lipocalin homolog
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US7118915B2 (en) 2001-09-27 2006-10-10 Pieris Proteolab Ag Muteins of apolipoprotein D
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
KR20150126724A (ko) 2007-09-28 2015-11-12 추가이 세이야쿠 가부시키가이샤 혈장 중 반응속도가 개선된 항-글리피칸-3 항체
US8937047B2 (en) * 2007-12-19 2015-01-20 General Electric Company Biokinetics of fast-clearing polypeptides
US8124725B2 (en) * 2007-12-19 2012-02-28 General Electric Company PDGF-Rβ binders

Also Published As

Publication number Publication date
EP2231706B1 (en) 2011-10-19
WO2009077569A1 (en) 2009-06-25
ES2375018T3 (es) 2012-02-24
ES2375018T7 (es) 2013-02-13
US8937047B2 (en) 2015-01-20
JP2011509926A (ja) 2011-03-31
US20090180954A1 (en) 2009-07-16
EP2231706B3 (en) 2012-07-18
CN101952314B (zh) 2016-04-20
ATE529445T1 (de) 2011-11-15
EP2231706A1 (en) 2010-09-29
CN101952314A (zh) 2011-01-19

Similar Documents

Publication Publication Date Title
JP7027480B2 (ja) 生物学的製剤の18f-放射性標識方法および組成物
JP2011509926A (ja) 迅速クリアランスポリペプチドの生体内動態
Zeng et al. Molecular imaging of apoptosis: from micro to macro
US8124725B2 (en) PDGF-Rβ binders
US8367040B2 (en) Contrast agents and methods for preparing contrast agents
CN109045313B (zh) 一种靶向her2的d型多肽放射性药物及制备方法
CN111228521A (zh) 一种Dar2多肽放射性药物及其制备方法
JP5986095B2 (ja) コンジュゲートおよび分子イメージングにおけるそれらの用途
US20180250426A1 (en) Contrast agents, methods for preparing contrast agents, and methods of imaging
CN116554146A (zh) 一种FAP-α特异性放射性药物及其应用
Farzin et al. Clinical aspects of radiolabeled aptamers in diagnostic nuclear medicine: A new class of targeted radiopharmaceuticals
CN112870390B (zh) 一种镓68标记的亲合体蛋白pet显像剂及应用
N’Guessan et al. Enhancing theranostic potential of anti-mesothelin sdAb through site-specific labeling at a unique conserved lysine by molecular engineering
JP6605331B2 (ja) 抗体−薬物複合体治療での使用のための免疫造影剤
US9844607B2 (en) Immuno imaging agent for use with antibody-drug conjugate therapy
KR20200114854A (ko) 탄산탈수소효소 9을 타겟으로 하는 암 진단 또는 치료용 펩타이드
Alhabardi et al. Synthesis, Radiolabeling, and Biological Evaluation of 68Ga‐Mucin1 and Its Folate Hybrid Peptide Conjugates for the Diagnosis of Ovarian Cancer
Pietzsch et al. Single Photon Emission Computed Tomography Tracer
Huynh The Evaluation of Radiometal Labeled Biomolecules for Imaging and Therapeutic Applications
JP2026515172A (ja) Alsバイオマーカーのインビボ画像化およびそのための手段
Cook The Development of Novel Platforms for the Imaging of Cancer by Positron Emission Tomography
Hua Research Progress on Asialoglycoprotein Receptor-Targeted Radiopharmaceuticals Designed for Hepatic Nuclear Medicine Imaging

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130917

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131213

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140117

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141218

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150407

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150501

R150 Certificate of patent or registration of utility model

Ref document number: 5745275

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250